18 07, 2021 Alessandro Parisi et al., Clinicians’ Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, “Real-Life”, Case-Control Study adlitterio663392022-10-21T09:31:52+02:00 Leggi di più
16 05, 2020 Alessandro Parisi et. al., Evaluation of Second-Line Anti-VEGF after First-Line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” Study Diatech Pharmacogenetics2020-11-03T15:11:21+01:00 Leggi di più
